Stephanie Sasse

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader et al. · Journal of Clinical Oncology · 2018 · 353 citations

Mhc Class, Immunology, Immunoediting +22

Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells

Elke Pogge von Strandmann, Venkateswara R. Simhadri, Bastian von Tresckow et al. · Immunity · 2007 · 337 citations · Full text

Natural Killer Cells, Cancer Immunosurveillance, Immunology +9

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe, Stephanie Sasse, Max S. Topp et al. · Blood · 2015 · 320 citations · Full text

Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe et al. · Journal of Clinical Oncology · 2019 · 217 citations

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

Kristina Fritsch, Benjamin Kasenda, Elisabeth Schorb et al. · Leukemia · 2016 · 180 citations · Full text